{{Rsnum
|rsid=2842951
|Gene=TPMT
|Chromosome=6
|position=18135452
|Orientation=plus
|GMAF=0.3163
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=TPMT
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 61.9 | 33.6 | 4.4
| HCB | 69.3 | 25.5 | 5.1
| JPT | 58.4 | 38.1 | 3.5
| YRI | 10.9 | 42.9 | 46.3
| ASW | 21.1 | 42.1 | 36.8
| CHB | 69.3 | 25.5 | 5.1
| CHD | 69.7 | 27.5 | 2.8
| GIH | 51.5 | 38.6 | 9.9
| LWK | 13.6 | 46.4 | 40.0
| MEX | 65.5 | 29.3 | 5.2
| MKK | 9.0 | 43.6 | 47.4
| TSI | 51.0 | 42.2 | 6.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2842951
|Name_s=rs2842951 C/T TPMT
|Gene_s=TPMT
|Feature=
|Evidence=PubMed ID:20157331
|Annotation=Risk or phenotype-associated allele: Not specified. Phenotype: This SNP was associated with clearance of docetaxel. Study size: 31. Study population/ethnicity: Patients with Non-Small-Cell Lung Carcinoma. Significance metric(s): p = 0.1013 (ANOVA); p = 0.0159 (QMIS); p = 0.0178 (KW) Type of association: PK.
|Drugs=docetaxel
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291806
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2842951
|overall_frequency_n=73
|overall_frequency_d=126
|overall_frequency=0.579365
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=69
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}